Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC
July 12th 2017Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).
Read More